Human TRAIL R3/TNFRSF10C Antibody Summary
Met1-Ala221
Accession # O14798
Applications
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Scientific Data
View Larger
Detection of TRAIL R3/TNFRSF10C in Human Blood Granulocytes by Flow Cytometry. Human peripheral blood granulocytes were stained with Mouse Anti-Human TRAIL R3/TNFRSF10C Monoclonal Antibody (Catalog # MAB6302, filled histogram) or isotype control antibody (Catalog # MAB002, open histogram), followed by Phycoerythrin-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0102B).
Reconstitution Calculator
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: TRAIL R3/TNFRSF10C
Human TRAIL R3, also known as DcR1 (Decoy Receptor 1), LIT, and TRID, is a glycosyl-phosphatidylinositol-linked membrane protein which binds TRAIL (Apo2 Ligand) with high affinity. In the new TNF superfamily nomenclature, TRAIL R3 is referred to as TNFRSF10C. TRAIL R3 has the TRAIL-binding extracellular cysteine-rich domains but lacks the intracellular signalling domain. As a result, binding of TRAIL to TRAIL R3 does not transduce an apoptosis signal. Expression of TRAIL R3 has been shown to protect cells bearing TRAIL R1 and/or TRAIL R2 from TRAIL-induced apoptosis. A second TRAIL decoy receptor, which binds TRAIL with high-affinity but antagonizes TRAIL-induced apoptosis, named TRAIL R4, DcR2 or TRUNDD, has also been reported. The human soluble TRAIL R3/Fc chimera neutralizes the ability of TRAIL to induce apoptosis.
Product Datasheets
Citations for Human TRAIL R3/TNFRSF10C Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
14
Citations: Showing 1 - 10
Filter your results:
Filter by:
-
Dominant negative effects of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 4 on TRAIL receptor 1 signaling by formation of heteromeric complexes.
Authors: Neumann S, Hasenauer J, Pollak N, Scheurich P
J Biol Chem, 2014-04-24;289(23):16576-87.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
TRAIL-engineered bone marrow-derived mesenchymal stem cells: TRAIL expression and cytotoxic effects on C6 glioma cells.
Authors: Tang X, Lu J, Tu H, Huang K, Fu R, Cao G, Huang M, Cheng L, Dai L, Zhang L
Anticancer Res, 2014-02-01;34(2):729-34.
Species: Rat
Sample Types: Whole Cells
Applications: Flow Cytometry -
TRAIL-engineered pancreas-derived mesenchymal stem cells: characterization and cytotoxic effects on pancreatic cancer cells.
Cancer Gene Ther., 2012-07-06;19(9):652-8.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
Dexamethasone counteracts the anti-osteoclastic, but not the anti-leukemic, activity of TNF-related apoptosis inducing ligand (TRAIL).
Authors: Zauli G, Rimondi E, Celeghini C, Milani D, Secchiero P
J. Cell. Physiol., 2010-02-01;222(2):357-64.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
Plasmacytoid dendritic cells express TRAIL and induce CD4+ T-cell apoptosis in HIV-1 viremic patients.
Authors: Stary G, Klein I, Kohlhofer S, Koszik F, Scherzer T, Mullauer L, Quendler H, Kohrgruber N, Stingl G
Blood, 2009-08-18;114(18):3854-63.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
Diallyl trisulfide increases the effectiveness of TRAIL and inhibits prostate cancer growth in an orthotopic model: molecular mechanisms.
Authors: Shankar S, Chen Q, Ganapathy S, Singh KP, Srivastava RK
Mol. Cancer Ther., 2008-08-01;7(8):2328-38.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
Differential effects of chemotherapeutic drugs versus the MDM-2 antagonist nutlin-3 on cell cycle progression and induction of apoptosis in SKW6.4 lymphoblastoid B-cells.
Authors: Barbarotto E, Corallini F, Rimondi E, Fadda R, Mischiati C, Grill V, Vaccarezza M, Celeghini C
J. Cell. Biochem., 2008-05-15;104(2):595-605.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells.
Authors: Toscano F, Fajoui ZE, Gay F, Lalaoui N, Parmentier B, Chayvialle JA, Scoazec JY, Micheau O, Abello J, Saurin JC
Oncogene, 2008-03-17;27(30):4161-71.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis.
Authors: Weinmann L, Wischhusen J, Demma MJ, Naumann U, Roth P, Dasmahapatra B, Weller M
Cell Death Differ., 2008-01-18;15(4):718-729.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis.
Authors: Locklin RM, Federici E, Espina B, Hulley PA, Russell RG, Edwards CM
Mol. Cancer Ther., 2007-12-07;6(12):3219-28.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
Blockade of death receptor-mediated pathways early in the signaling cascade coincides with distinct apoptosis resistance in cutaneous T-cell lymphoma cells.
Authors: Braun FK, Fecker LF, Schwarz C, Walden P, Assaf C, Durkop H, Sterry W, Eberle J
J. Invest. Dermatol., 2007-05-10;127(10):2425-37.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma.
Authors: Singh TR, Shankar S, Srivastava RK
Oncogene, 2005-07-07;24(29):4609-23.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
Low-Level Endothelial TRAIL-Receptor Expression Obstructs the CNS-Delivery of Angiopep-2 Functionalised TRAIL-Receptor Agonists for the Treatment of Glioblastoma
Authors: Nivetha Krishna Moorthy, Oliver Seifert, Stephan Eisler, Sara Weirich, Roland E. Kontermann, Markus Rehm et al.
Molecules
-
Designed ferritin nanocages displaying trimeric TRAIL and tumor-targeting peptides confer superior anti-tumor efficacy
Authors: JD Yoo, SM Bae, J Seo, IS Jeon, SMP Vadevoo, SY Kim, IS Kim, B Lee, S Kim
Sci Rep, 2020-11-17;10(1):19997.
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsReviews for Human TRAIL R3/TNFRSF10C Antibody
Average Rating: 4 (Based on 1 Review)
Have you used Human TRAIL R3/TNFRSF10C Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
THP-1 cells were treated with LPS (100 mg/ml) for 24h. Total cell lysates were subjected to western blot. PVDF membrane were probed with 1mm/ml Human TRAIL R3 Antibody (MAB6302). A specific band was detected for TRAIL R3 at approximately 28 kDa. This experiment was conducted under reducing conditions.
